Back to Clinical Trials
Phase 3Recruiting

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Sponsored by Bristol-Myers Squibb

About this study

The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

Where this study is enrolling (5)

  • University of California Davis Health

    Sacramento, California

    Call 916-734-3588

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • University of South Florida

    Tampa, Florida

    Call 813-396-9478

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • University of Chicago Medical Center

    Chicago, Illinois

    I'm interested

  • University of Louisville, Norton Children's Research Institute

    Louisville, Kentucky

    Call 502-629-5606

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

    Call 414-955-0619

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Who can participate

Inclusion criteria

  • ✓Has a diagnosis of multiple sclerosis (MS) as defined by the 2017 revision of the McDonald Criteria with a relapsing remitting course of disease.
  • ✓Meets at least 1 of the following criteria for disease activity:
  • ✓i) At least 1 MS relapse/attack in the previous year prior to screening.
  • ✓ii) At least 2 MS relapses/attacks in the previous 2 years prior to screening.
  • ✓iii) Evidence of 1 or more gadolinium-enhancing (GdE) lesions on magnetic resonance imaging (MRI) within 6 months prior to baseline (including screening MRI).
  • ✓\- Has an Expanded Disability Status Scale (EDSS) score of 0 to 5.5, both inclusive.

Exclusion criteria

  • ✕Diagnosis of progressive forms of MS.
  • ✕Active or chronic disease of the immune system other than MS.
  • ✕Clinically relevant cardiovascular, hepatic, neurological other major systematic disease.
  • ✕Other protocol-defined Inclusion/Exclusion criteria apply.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.